Thursday, July 31, 2014 Last update: Yesterday, 11:33 PM - All Company Technology News Since 1996

RedPath Welcomes Alan Fishman as New Chief Financial Officer

Companies mentioned in this article: RedPath Integrated Pathology, Inc.

PITTSBURGH -- (BUSINESS WIRE) -- RedPath Integrated Pathology, Inc., a leader in molecular diagnostics, announced the appointment of Alan Fishman as chief financial officer. As CFO, Mr. Fishman is responsible for overseeing all financial functions and, along with the other members of the RedPath management team, coordinating the business affairs of the company.

"We are thrilled to add Mr. Fishman to the RedPath team at this important time in the development of our company. He is a hands-on, strategic, finance, and operations executive with a talent for raising capital and working with venture funded companies,” stated Dennis M. Smith, Jr., MD, president and chief executive officer of RedPath. “He will play an integral part in driving financial performance and both short- and long-term growth for the company,” said Dr. Smith.

Prior to joining RedPath, Mr. Fishman held financial leadership roles at 11 venture and private equity funded firms and was a partner with Tatum, LLC, for five years. Mr. Fishman is a licensed CPA and received a bachelor’s degree in finance from the University of Illinois at Urbana-Champaign and an MBA from the Kelley School of Business at Indiana University.

About RedPath Integrated Pathology
RedPath Integrated Pathology, Inc. is a Pittsburgh-based molecular diagnostics laboratory focused on providing novel solutions for clinicians. RedPath’s patented PathFinderTG® platform produces mutational profiles to help physicians resolve complex diagnostic dilemmas in patients who are at risk of cancer. RedPath performs all clinical testing and R&D in its state-of-the-art, CLIA-certified and CAP-accredited laboratory.

The PathFinderTG platform is supported by more than 20 years of scientific and clinical research, and studies using it have been published in more than 200 peer-reviewed journals, including The New England Journal of Medicine. Based on the strong clinical data supporting this platform, RedPath has received positive coverage decisions from Medicare and private payers. For more information about RedPath Integrated Pathology visit or contact Andrew Mignatti at 412-224-6100.

Copyright © Business Wire 2014

RedPath Integrated Pathology
Andrew Mignatti, 412-224-6100